These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37723439)

  • 1. Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score.
    Truong TN; Pham TND; Hoang LB; Nguyen VT; Dao HV; Dao DVB; Alessy S; Pham HB; Pham TTT; Nguyen LDD; Nguyen K; Abaalkhail F; Manal M; Mawardi M; AlZahrani M; Alswat K; Alghamdi H; Sanai FM; Siddiqui MA; Nguyen NH; Vaidya D; Phan HT; Johnson PJ; Alqahtani SA; Dao DY
    BMC Cancer; 2023 Sep; 23(1):875. PubMed ID: 37723439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
    Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
    Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
    Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
    Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe.
    Beudeker BJB; Fu S; Balderramo D; Mattos AZ; Carrera E; Diaz J; Prieto J; Banales J; Vogel A; Arrese M; Oliveira J; Groothuismink ZMA; van Oord G; Hansen BE; de Man RA; Debes JD; Boonstra A
    Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.
    Cagnin S; Donghia R; Martini A; Pesole PL; Coletta S; Shahini E; Boninsegna G; Biasiolo A; Pontisso P; Giannelli G
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
    Yang JD; Addissie BD; Mara KC; Harmsen WS; Dai J; Zhang N; Wongjarupong N; Ali HM; Ali HA; Hassan FA; Lavu S; Cvinar JL; Giama NH; Moser CD; Miyabe K; Allotey LK; Algeciras-Schimnich A; Theobald JP; Ward MM; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Srivastava S; Rinaudo JA; Gores GJ; Feng Z; Marrero JA; Roberts LR
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):531-538. PubMed ID: 30464023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study.
    Villa E; Donghia R; Baldaccini V; Tedesco CC; Shahini E; Cozzolongo R; Ascari S; Pesole PL; Coletta S; Critelli RM; Lasagni S; Schepis F; Semellini F; Giannelli G
    Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GALAD score and a proposal for GALADUS model for detecting hepatocellular carcinoma in Vietnamese patients with chronic liver disease.
    Phuong PC; Khoa MT; Loi NT; Quynh VTT; Luan ND; Mai NTH; Dung NV; Hung NQ; Lieu DQ; Nam LV; Tra DT; Thai PV; Duc NM
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1111-1122. PubMed ID: 38375717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.
    An C; Kim DY; Choi JY; Han KH; Roh YH; Kim MJ
    BMC Cancer; 2018 Sep; 18(1):915. PubMed ID: 30249190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study.
    Huang C; Fang M; Xiao X; Wang H; Gao Z; Ji J; Liu L; Gu E; Li Y; Wang M; Gao C
    Liver Int; 2022 Jan; 42(1):210-223. PubMed ID: 34679250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
    Chalasani NP; Porter K; Bhattacharya A; Book AJ; Neis BM; Xiong KM; Ramasubramanian TS; Edwards DK; Chen I; Johnson S; Roberts LR; Kisiel JB; Reddy KR; Singal AG; Olson MC; Bruinsma JJ
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):173-182.e7. PubMed ID: 34391922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis.
    Singal AG; Tayob N; Mehta A; Marrero JA; Jin Q; Lau J; Parikh ND
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):953-955.e2. PubMed ID: 33864933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
    Yang T; Wang N; Wang F; Liu H; Shen F; Lv G
    BMJ Open; 2023 Sep; 13(9):e076467. PubMed ID: 37723113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.
    Tzartzeva K; Obi J; Rich NE; Parikh ND; Marrero JA; Yopp A; Waljee AK; Singal AG
    Gastroenterology; 2018 May; 154(6):1706-1718.e1. PubMed ID: 29425931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing Surveillance Strategies for Hepatocellular Carcinoma: A New Era of Efficacy and Precision.
    Singal AG; Ng M; Kulkarni A
    J Clin Exp Hepatol; 2024; 14(6):101448. PubMed ID: 38946864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial.
    Park JH; Park MS; Lee SJ; Jeong WK; Lee JY; Park MJ; Han K; Nam CM; Park SH; Lee KH
    BMC Cancer; 2017 Apr; 17(1):279. PubMed ID: 28420329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.
    Lin N; Lin Y; Xu J; Liu D; Li D; Meng H; Gallant MA; Kubota N; Roy D; Li JS; Gorospe EC; Sherman M; Gish RG; Abou-Alfa GK; Nguyen MH; Taggart DJ; Van Etten RA; Hoshida Y; Li W
    Hepatol Commun; 2022 Jul; 6(7):1753-1763. PubMed ID: 35244350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
    Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.